Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $7.30 USD
Change Today -0.2144 / -2.85%
Volume 5.6K
As of 5:20 PM 05/27/15 All times are local (Market data is delayed by at least 15 minutes).

aquinox pharmaceuticals inc (AQXP) Snapshot

Open
$7.55
Previous Close
$7.51
Day High
$7.63
Day Low
$7.30
52 Week High
03/11/15 - $12.28
52 Week Low
10/13/14 - $5.50
Market Cap
78.3M
Average Volume 10 Days
7.3K
EPS TTM
$-2.50
Shares Outstanding
10.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AQUINOX PHARMACEUTICALS INC (AQXP)

Related News

No related news articles were found.

aquinox pharmaceuticals inc (AQXP) Related Businessweek News

No Related Businessweek News Found

aquinox pharmaceuticals inc (AQXP) Details

Aquinox Pharmaceuticals Inc., a clinical-stage pharmaceutical company, engages in discovering and developing targeted therapeutics for diseases in the areas of inflammation and immuno-oncology. The company primarily focuses on anti-inflammatory product candidates targeting SHIP1, a key regulator of a cellular signaling pathway in immune cells. Its lead product candidate is AQX-1125, a small molecule activator of SHIP1 that is in Phase II clinical trials for chronic obstructive pulmonary disease, bladder pain syndrome/interstitial cystitis, and atopic dermatitis. The company was formerly known as 6175813 Canada Inc. and changed its name to Aquinox Pharmaceuticals Inc. in March 2006. Aquinox Pharmaceuticals Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

24 Employees
Last Reported Date: 05/12/15
Founded in 2003

aquinox pharmaceuticals inc (AQXP) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $365.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $181.1K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $302.4K
Compensation as of Fiscal Year 2014.

aquinox pharmaceuticals inc (AQXP) Key Developments

Aquinox Pharmaceuticals Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Aquinox Pharmaceuticals Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company’s net loss was $6.4 million compared to a net loss of $4.2 million for the first quarter of 2014. This increase was primarily due to the ongoing advancement of AQX-1125 through the FLAGSHIP, LEADERSHIP and KINSHIP clinical trials and costs associated with operating as a public company. Net loss before income taxes was $6,412,000 compared to $4,228,000 a year ago. Net loss per basic and diluted common stock was $0.60 compared to $1.28 a year ago. Research and development expenses increased to $4.6 million from $1.9 million in the first quarter of 2014. This increase was primarily driven by the ongoing advancement of AQX-1125 through the FLAGSHIP, LEADERSHIP and KINSHIP clinical trials.

Aquinox Pharmaceuticals Completes Enrollment in the Phase 2 KINSHIP Trial of AQX-1125 in Atopic Dermatitis

Aquinox Pharmaceuticals Inc. announced that it has reached its target enrollment in the Phase 2 KINSHIP trial of AQX-1125 for the treatment of atopic dermatitis. The KINSHIP clinical trial is being conducted at investigative sites in Canada as a randomized, double-blind, multicenter, placebo-controlled Phase 2 trial evaluating the efficacy and safety of AQX-1125 in approximately 50 adult patients with mild to moderate atopic dermatitis as a proof-of-concept trial in this indication. The KINSHIP trial's primary endpoint is change from baseline in Total Lesion Symptom Score after 12 weeks of treatment. Secondary endpoints include safety, pharmacokinetics and additional efficacy endpoints, including the analyses of biopsies. Top line data from the KINSHIP trial is anticipated by the first quarter of 2016.

Aquinox Pharmaceuticals Inc. Presents at Bloom Burton & Co. Inc. Healthcare Investor Conference, May-05-2015 11:00 AM

Aquinox Pharmaceuticals Inc. Presents at Bloom Burton & Co. Inc. Healthcare Investor Conference, May-05-2015 11:00 AM. Venue: Sheraton Centre Toronto Hotel (Corner of York and Queen St. West), Toronto, Ontario, M5H 3M9, Canada. Speakers: David J. Main, Co-Founder, Chairman, Chief Executive Officer and President.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AQXP:US $7.30 USD -0.2144

AQXP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AQXP.
View Industry Companies
 

Industry Analysis

AQXP

Industry Average

Valuation AQXP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AQUINOX PHARMACEUTICALS INC, please visit www.aqxpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.